Lead team to effectively execute robust insights generation plans for Jynarque, Vadadustat, Sibeprenlimab, Centanafadine, Ulotarant and Nuedexta.•Leveraged market research insights and collaborated with cross-functional teams to course correct softening Jynarque performance through recommended improvements on Field Force execution, tactics, and message delivery•Led the effort to drive deeper learnings among HCP segments and to leverage those insights to shape marketing and field sales force focus, which resulted into converting more HCPs into Jynarque prescribers and loyalists•Embraced the new Otsuka Customer Engagement Model by creating and delivering field execution reports that highlighted issues and opportunities across all Otsuka Sales regions

Led team to optimize Rexulti's in-line performance and prepare for the launch of lifecycle indications launch.•Spearheaded essential LCM research for Agitation in Alzheimer's and PTSD, from strategic planning to execution•Elevated the delivery and communication of Competitive Intelligence to a new level of excellence•Guided and facilitated War Game sessions to effectively prepare for competitive threats and emerging challenges•Translated insights gleaned from attitudinal segmentation into tangible field execution strategies, effectively bridging the gap between analysis and action

Responsible for leveraging HCP, consumer, and caregiver insights to drive Rexulti in-line performance.•Identified patient and HCP characteristics to strategically position Rexulti for earlier and first-line utilization•Harnessed variances within consumer segments to optimize media buying and creative campaign strategies•Implemented substantial enhancements in HCP and consumer tracking studies, yielding valuable insights that informed multiple successful DTC campaigns

Managed a team of Insight and Analytics Leaders, ensuring the seamless execution of insight-driven reporting, advanced analytics, and primary research, contributing to Farxiga's achievement as the most successful diabetes product launch in eight years.

Championed primary and analytical initiatives for Bydureon, resulting in a more profound comprehension of post launch brand performance and subsequent refinement of pivotal messages within the professional VisAid.

Spearheaded a Center of Excellence team and established a robust, sustainable analytics infrastructure that played a pivotal role in proactively tackling access-related challenges for prominent brands such as Plavix and Abilify, amidst the evolving dynamics of the payer landscape.

Steered all global market research efforts for the Muraglitazar global professional campaign and trade name process while fostering robust collaborative ties between Global and US teams, as well as our strategic joint venture partner, Merck.

Directed all global market research and brand planning work streams for the early diabetes and obesity portfolios.

Guided global MR for entecavir, a pre-launch hepatitis B compound and portfolio-wide forecasting capabilities.

Identified business opportunities and recommended prioritized marketing levers by applying a dynamic approach to map the patient’s journey through disease progression for high potential phase II/III compounds.

Developed the pricing strategy for new launches and measured the effectiveness of past pricing strategies for rebated brands by working with the Managed Markets team to craft action plans for under-performing accounts.

Examined the value of pull-through initiatives by comparing actual results to previously established sales and market share objectives for priority US Managed Market customers.

Responsible for designing the curriculum and teaching “Analytical Methods for Health Policy” (HP 710), a graduate-level class focused on leveraging modeling techniques to analyze major health policy issues.